Another study confirms detrimental effects of delaying hepatitis C treatment
When a short course of sofosbuvir/ledipasvir fails, some people can be cured of hepatitis C with a double treatment duration
Sofosbuvir-based treatment safe and effective in advanced kidney disease
Merck's grazoprevir/elbasvir combo cures 99% of hepatitis C in chronic kidney disease
Sofosbuvir plus pegylated interferon/ribavirin is highly effective for people with hard-to-treat genotype 3 hepatitis C
Sofosbuvir, daclatasvir and ribavirin cures hepatitis C for most people with advanced cirrhosis or liver transplants
New EASL guidelines prioritise interferon-free hepatitis C treatment
